Decitabine dosage in myelodysplastic syndromes
نویسنده
چکیده
contained a chromosome 7 abnormality (also mostly monosomy 7). Four of 11 patients with complex karyotype including aberrations of chromosome 7 showed cytogenetic responses (Figure 1; Table 1) compared with 2 responders of 9 patients with complex karyotype not containing a chromosome 7 abnormality. This high response rate in patients with chromosome 7 abnormalities is in stark contrast to the notoriously low response rate of MDS patients receiving conventional low-dose therapy with AraC.4 In summary, the optimal dose and schedule of DAC for a nonintensive, outpatient treatment of high-risk MDS patients may not yet be defined. The Bayesian design has not been uniformly accepted as the optimal methodology to identify treatment superiority.5 Systematic evaluation of cytogenetic responses in different cytogenetic subgroups of MDS and acute myeloid leukemia will continue to be a very valuable and robust surrogate parameter to compare efficiency of azanucleoside schedules6 and other novel agents7 used to treat MDS.
منابع مشابه
Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established. In this study, an observational, retrospective and multi-center analysis was performed to explore the decitabine schedule for the treatment of MDS. A total of 79 patients received reduced dosage decitabine treatment (15 ...
متن کاملEpigenetic effects of decitabine on acute lymphoblastic and acute promyelocytic leukemia cells
Background: Decitabine (5-aza-2'-deoxycytidine, DAC) is a deoxycytidine analog currently used as an effective drug against myelodysplastic syndromes and acute myeloid leukemia. Although various studies have pointed out the epigenetic effects of this drug, its epigenetic mechanisms in different leukemic cell lines are not specified. In this lab trial study, possible epigenetic effects of decitab...
متن کاملSpotlight on decitabine for myelodysplastic syndromes in Chinese patients
Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal hematopoietic stem cell malignancies with advanced median age. The silencing of tumor suppressor genes caused by DNA hypermethylation plays a crucial role in the pathogenesis of MDS. Decitabine, the available hypomethylating agent, is successfully used for the treatment and improves the outcome of MDS, and has become one of th...
متن کاملNew Drugs Drug News
304 P&T® • June 2006 • Vol. 31 No. 6 NEW DRUGS Decitabine for Myelodysplastic Syndromes Decitabine injection (Dacogen, MGI Pharma, Inc./SuperGen, Inc.) has been approved by the U.S. Food and Drug Administration (FDA) for patients with myelodysplastic syndromes (MDS). MDS comprises a group of bone marrow diseases characterized by the production of poorly functioning and immature blood cells. Ove...
متن کاملDecitabine in the treatment of myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias and a propensity to transform into acute myeloid leukemia. There are few treatment options available for patients with MDS. Studies into the molecular biology of MDS have demonstrated abnormal patterns of DNA methylation th...
متن کامل